Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Symptoms and General Pathology

Skin and Connective Tissue Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Blood and Lymph Conditions

Immune System Diseases

Rare Diseases

Lung Neoplasms

Neoplasm Metastasis

Breast Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Lymphoma

Neutropenia

Agranulocytosis

Leukopenia

Cytopenia

Hematologic Diseases

Leukocyte Disorders

Ovarian Cancer

Ovarian Epithelial Cancer

Lymphosarcoma

Granulocytopenia

Neulasta 6mg single administration per cycle of chemotherapy starting with cycle 1

Commercial pegfilgrastim 6mg single subcutaneous fixed-dose

Neulasta (pegfilgrastim)

The purpose of this study is to assess pegfilgrastim starting with the first cycle versus secondary prophylaxis on neutropenic events (including neutropenia +/- fever, dose delays, dose reductions, and hospitalizations) in older patients receiving chemotherapy.

A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer

A Randomized, Open Label, Multicenter Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis as an Adjunct to Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer

Amgen

Global Development Leader

Sarcoma

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Soft Tissue Sarcoma

Antineoplastic Agents

All Drugs and Chemicals

Hematinics

Anti-Infective Agents

Doxorubicin

Liposomal doxorubicin

Ifosfamide

Mitogens

Isophosphamide mustard

Darbepoetin alfa

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

Antineoplastic Agents, Alkylating

Alkylating Agents

Growth Factors = Aranesp (Darbepoetin Alfa) and Pegfilgrastim (Neulasta)

Aranesp (darbepoetin alfa)

Adriamycin

Saroj Vadhan-Raj, M.D.

To determine the percentage of patients and number of cycles in which a packed red blood cell transfusion was administered due to anemia and in which antibiotics were administered due to neutropenic fever.

The use of hematopoietic growth factors have been shown to reduce neutropenic complications and red cell transfusion requirements associated with chemotherapy. This trial will study the combination of pegfilgrastim and darbepoetin alfa administered once per cycle of chemotherapy. Prior experience with growth factors in this setting provides historical data for comparison of safety and activity of these newer longer acting growth factors in reducing the incidence of febrile neutropenia requiring antibiotics and anemia requiring transfusions. The once dosing per cycle would simplify the patient management and would improve patient convenience and compliance.

Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide

A Pilot Study of Aranesp (Darbepoetin Alfa) and Pegfilgrastim (Neulasta) in Patients With Sarcoma Receiving Adriamycin and Ifosfamide

M.D. Anderson Cancer Center

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer	NCT00277160	Neutropenia Breast Cancer Lung Cancer Non-Hodgkin's L... Ovarian Cancer	Neulasta (pegfi...	65 Years -	Amgen
Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide	NCT00283621	Sarcoma	Aranesp (darbep... Neulasta (pegfi... Adriamycin Ifosfamide	18 Years - 65 Years	M.D. Anderson Cancer Center

Spots Global Cancer Trial Database for neulasta (pegfilgrastim)